Drug Profile
Research programme: anti-CD3 monoclonal antibody - Affimed Therapeutics
Alternative Names: AFM 15; anti-CD3 monoclonal antibody - AffimedLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Affimed Therapeutics
- Class Monoclonal antibodies
- Mechanism of Action CD3 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Allotransplant rejection
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Allotransplant-rejection in Germany
- 25 Jul 2005 This programme is available for licensing (http://www.affimed.com)
- 25 Jun 2005 Preclinical trials in Allotransplant rejection in Germany (unspecified route)